AngioDynamics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James C. Clemmer
- Full Time Employees
- 748
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 14 Plaza Drive Latham NY United States of America 12110
- IPO Date
- Jun 1, 2004
- CIK
- 0001275187
- Website
- angiodynamics.com
- Similar Companies
- Business
- AngioDynamics, Inc. designs, manufactures, and markets innovative medical devices for minimally invasive, image-guided treatments of peripheral vascular disease, oncology, and cardiovascular conditions; its core products span oncology offerings including the NanoKnife System for precise tumor ablation, Habib 4X Bipolar Resection Device, and IsoLoc Endorectal Balloon; venous therapies such as VenaCure EVLT 1470 Pro Laser System and procedure packs; vascular interventions featuring the Auryon Atherectomy System, AngioVac and AlphaVac mechanical thrombectomy systems, and ports; and diagnostic tools like the Model 1500X RF Generator and Alatus balloon. The company, founded in 1988 and headquartered in Latham, New York, operates globally with facilities in the United States, Europe, and Australasia, serving interventional radiologists, nephrologists, surgeons, and healthcare providers treating critical limb ischemia, pulmonary embolism, and cancer patients. In fiscal 2026 first quarter, AngioDynamics reported strong growth including 20.1% increase in Auryon sales to $16.5 million, 41.2% rise in mechanical thrombectomy sales to $11.3 million driven by AngioVac and AlphaVac, and 26.7% growth in NanoKnife sales to $6.4 million; it enrolled the first patient in the AMBITION BTK trial for Auryon in below-the-knee lesions and the RECOVER-AV trial for AlphaVac in intermediate-risk pulmonary embolism across Europe, Canada, and Hong Kong.
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet
AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of “Moderate Buy” by Analysts
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AngioDynamics (ANGO) Upgraded to Buy: Here's Why
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
AngioDynamics Growing, But With More Noise Than The Street Likes
AngioDynamics Q3 Earnings Call Highlights
AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript
AngioDynamics (ANGO) Reports Q3 Loss, Tops Revenue Estimates